CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in CNS Pharmaceuticals, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −11 vs. Q3 2022
- Shares held
- 139.4K
- −1.16M (−89.3%) vs. Q3 2022
- Total value
- $335.0K
- +$103.0K (+44.4%) vs. Q3 2022
- New holders
- 4
- 0 more added
- Sold out
- 15
- 6 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CNSP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.34M |
| Q1 2026 | 12 | $348.7K |
| Q4 2025 | 10 | $652.4K |
| Q3 2025 | 8 | $221.5K |
| Q2 2025 | 11 | $421.8K |
| Q1 2025 | 7 | $55.2K |
| Q4 2024 | 21 | $297.3K |
| Q3 2024 | 14 | $75.3K |
| Q2 2024 | 10 | $227.8K |
| Q1 2024 | 19 | $351.0K |
| Q4 2023 | 16 | $425.3K |
| Q3 2023 | 12 | $131.7K |
| Q2 2023 | 12 | $234.4K |
| Q1 2023 | 13 | $190.5K |
| Q4 2022 | 10 | $335.0K |
| Q3 2022 | 21 | $232.0K |
| Q2 2022 | 23 | $343.5K |
| Q1 2022 | 20 | $589.0K |
| Q4 2021 | 24 | $828.0K |
| Q3 2021 | 20 | $1.44M |
| Q2 2021 | 20 | $2.64M |
| Q1 2021 | 19 | $3.04M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding CNS Pharmaceuticals, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Advisor Group Holdings, Inc. | 1 | $0 | 0.00% | −9−90.0% | Reduced |
| Plante Moran Financial Advisors, LLC | 1 | $2 | 0.00% | +1 | New |
| Gradient Investments LLC | 7 | $17 | 0.00% | −193−96.5% | Reduced |
| The PNC Financial Services Group, Inc. | 8 | $20 | 0.00% | +8 | New |
| Bank of America Corp | 25 | $60 | 0.00% | −152−85.9% | Reduced |
| Global Retirement Partners, LLC | 34 | $82 | 0.00% | −966−96.6% | Reduced |
| Wells Fargo & Company | 482 | $1.16K | 0.00% | −11,728−96.1% | Reduced |
| UBS Group AG | 1,213 | $2.91K | 0.00% | +1,213 | New |
| Tower Research Capital LLC (TRC) | 4,377 | $11.0K | 0.00% | −30,149−87.3% | Reduced |
| Armistice Capital, LLC | 133,229 | $319.8K | 0.01% | +133,229 | New |
| Vanguard Group Inc | 0 | $0 | 0.00% | −453,615−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −203,548−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −129,016−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −127,922−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −90,487−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −56,800−100.0% | Sold out |
| FSM Wealth Advisors, LLC | 0 | $0 | 0.00% | −40,000−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −32,094−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −25,250−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −19,645−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −18,549−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −18,000−100.0% | Sold out |
| Alpha Cubed Investments, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Prime Capital Investment Advisors, LLC | 0 | $0 | 0.00% | −10,727−100.0% | Sold out |